Aureon Laboratories to Collaborate with Pfizer Inc. to Establish Quantitative Biometrics for Assessing Therapeutic Response of Prostate Cancer Patients Treated with Hormone Therapy

YONKERS, N.Y.--(BUSINESS WIRE)--Aureon Laboratories, Inc. today announced a new phase in a research collaboration with Pfizer, Inc. that shall establish quantitative biometrics for assessing therapeutic response derived from studies focusing on prostate cancer. The collaboration will utilize Aureon’s integrated systems pathology approach, whereby data generated from tissue morphometry, multiplexed-protein biomarkers, and in situ RNA expression are integrated with patient clinical information and associated with clinical outcome.